Biomea Fusion (BMEA) Retained Earnings (2020 - 2026)
Biomea Fusion (BMEA) posted Retained Earnings of -$461.5 million for Q1 2026, down 2.76% sequentially from -$449.0 million in Q4 2025, and down 10.8% YoY from -$517.3 million in Q1 2025.
Biomea Fusion (BMEA) Retained Earnings (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Retained Earnings for 7 years, with the latest figure at -$461.5 million in Q1 2026.
- Quarterly Retained Earnings fell 10.8% year-over-year to -$461.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$461.5 million (down 10.8% YoY) and the FY2025 annual result came in at -$449.0 million, down 15.96% from the prior year.
- Retained Earnings fell to -$461.5 million in Q1 2026 per BMEA's latest filing, from -$449.0 million in the prior quarter.
- Over five years, Retained Earnings peaked at $423.2 million in Q1 2024 and troughed at -$461.5 million in Q1 2026.
- A 5-year average of -$187.0 million and a median of -$213.9 million in 2023 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 41805900.0% in 2023, down 1091147.06% in 2023.
- Over 5 years, Retained Earnings stood at -$1000.0 in 2022, then jumped by 41805900.0% to $418.1 million in 2023, then tumbled by 192.63% to -$387.3 million in 2024, then fell by 15.96% to -$449.0 million in 2025, then fell by 2.76% to -$461.5 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$461.5 million, -$449.0 million, and -$453.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | 481.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 481.92 Mn |
| Mar 31, 2026 | -461.46 Mn |
| Dec 31, 2025 | -449.05 Mn |
| Sep 30, 2025 | -453.66 Mn |
| Jun 30, 2025 | -437.30 Mn |
| Mar 31, 2025 | -416.50 Mn |
| Dec 31, 2024 | -387.25 Mn |
| Sep 30, 2024 | -357.90 Mn |
| Jun 30, 2024 | -325.16 Mn |
| Mar 31, 2024 | 423.20 Mn |
| Dec 31, 2023 | 418.06 Mn |
| Sep 30, 2023 | -213.90 Mn |
| Jun 30, 2023 | -185.51 Mn |
| Mar 31, 2023 | -160.60 Mn |
| Dec 31, 2022 | -1,000.00 |
| Sep 30, 2022 | -106.26 Mn |
| Jun 30, 2022 | -17,000.00 |
| Mar 31, 2022 | -66.11 Mn |
| Dec 31, 2021 | -10,000.00 |
| Sep 30, 2021 | 226.36 Mn |